---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-314422"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:39:47.519007+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kymera prices upsized $602M public offering; net ~$656M for pipeline

## Summary
- Priced 7,000,000 shares at $86.00 per share; gross proceeds $602M.
- Underwriters exercised option to purchase additional 1,050,000 shares in full.
- Net proceeds estimated at ~$656.1M after discounts and expenses.
- Cash runway extended into 2029; funds to advance degrader pipeline and working capital.
- Offering expected to close December 11, 2025.

## SEC filing metadata
- accession: 0001193125-25-314422
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525314422/0001193125-25-314422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525314422/d89982d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-314422
- JSON: https://secwatch.observer/filing/0001193125-25-314422.json
- Plain text: https://secwatch.observer/filing/0001193125-25-314422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.